|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Tumor BRCA1/2 testing was performed for 315 (77.6%) of the 406 eligible OC samples, of which 305 (96.8%) were successful.
|
31076742 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These genes are associated with an estimated lifetime risk of EOC of 13% to 60% for BRCA1 variants and 10% to 25% for BRCA2 variants, with lower risks associated with remaining genes.
|
31099061 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
|
31699415 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Analyses performed under logistic model, linear mixed model, and model incorporating correlations identified nine significant associations with three gynecologic diseases including four novel findings (rs79219469:C > T, LINC02183, P = 3.3 × 10<sup>-8</sup> and rs567534295:C > T, BRCA1, P = 3.1 × 10<sup>-8</sup> with OC, rs150806792:C > T, INS-IGF2, P = 4.9 × 10<sup>-8</sup> and rs140991990:A > G, SOX9, P = 3.3 × 10<sup>-8</sup> with UCC).
|
31488892 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In the present study, 21 BRCA1 and BRCA2 pathogenic variants were detected in 30 patients and BRCA1/2 mutations were significantly associated with a family history of breast/ovarian cancer.
|
31706072 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH).
|
31797087 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A simultaneous detection of germline and somatic mutations in ovarian cancer (OC) using tumor materials is considered to be cost-effective for <i>BRCA1/2</i> testing.
|
31788999 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Germline mutations (eg, BRCA1/2) have prognostic and treatment implications for ovarian cancer (OVCA) patients.
|
31600840 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The clinicopathological parameters of 36 EOC patients carrying germline BRCA1/2 DM were compared to high-grade serous EOC women of the COEUR cohort with known germline BRCA1/BRCA2 mutation carrier status (n = 376 non-carriers, n = 65 BRCA1 and n = 38 BRCA2).
|
31753525 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
BRCA1-driven OCs demonstrate the plasticity of BRCA1 status during the treatment course.
|
31693165 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We searched and evaluated all primary literature on the use of IHC for evaluating BRCA1 and BRCA2 proteins expression in EOC.
|
31719105 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Comprehensive Profiling of BRCA1 and BRCA2 Variants in Breast and Ovarian Cancer in Chinese Patients.
|
31825140 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Overall, 178/2192 (8.1%) evaluable OC women showed pathogenic germline mutations in BRCA genes (84 BRCA1;94 BRCA2).
|
31253107 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Deleterious mutations in BRCA1 or BRCA2 genes increase a woman's lifetime risk of breast and ovarian cancer.
|
29863445 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the BRCA1 and BRCA2 genes are associated with an increased risk for developing breast and ovarian cancer.
|
30561604 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
The study includes 1246 individuals assessed for BRCA1/2 genetic testing in Navarra, during 2000-2016, and a cohort of BC (n = 4384) and OC (n = 561) from the population-based Navarra Cancer Registry.
|
31771539 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
PARP inhibitors are also approved as active therapy for women with germline or tumour BRCA1/2 mutations and recurrent EOC treated with three or more prior lines of therapy.
|
30895466 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The clinical development of PARP inhibitors in ovarian cancer patients with germline BRCA1/2 mutations and sporadic high-grade serous ovarian cancer is ongoing.
|
30215333 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Overall, LGRs accounted for 16.1% (5/31) of BRCA1 pathogenic variants, and were detected in 2.3% (5/218) of all FBOC patients.
|
31174498 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
<b>Methods:</b> 255 <i>BRCA1/2</i>-negative Chinese familial breast and/or ovarian cancer (FBOC) patients were recruited for <i>FANCC</i> germline mutations screen.
|
30967997 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
|
31500890 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations of BRCA1 and BRCA2 predispose individuals to a high risk of breast and ovarian cancer, and elevated risk of other cancers, including those of the pancreas and prostate.
|
31464824 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
|
30872026 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A noteworthy example is treatment of TNBC and epithelial ovarian cancer harboring BRCA1/2 germline mutations using platinum salts and/or PARP inhibitors.
|
30661659 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
NGS-based multiple gene panel resequencing in combination with a high resolution CGH-array was used to identify genetic risk factors for hereditary breast and/or ovarian cancer in 237 high risk patients who were previously tested negative for pathogenic BRCA1/2 variants.
|
30426508 |
2019 |